HIGHLIGHTS

The National Science Foundation’s Center for Disruptive Musculoskeletal Innovations (CDMI) held its third annual fall symposium at the UCSF Mission Bay campus during September 29-30, 2016.  The event, which was attended by researchers, clinicians and industry members, presented the center’s summary of its second year’s accomplishments as well as selecting the 2016-2017 project grant awardees. More than 75 center members attended, in addition to being broadcast via webcast to remote CDMI members.

The Center for Disruptive Musculoskeletal Innovations (CDMI) – a collaboration funded by the National Science Foundation between researchers at the University of California, San Francisco and the University of Toledo – completed its first year with great success.

“The CDMI has gained great momentum since its launch in 2014.” Jeffrey Lotz, PhD, the Center’s Director, said. “At the close of our first year, we have been able to leverage the $40,000 per industry member fee by almost $2,400,000 in cash support and more than $500,000 in capital and in-kind contributions. We are proud of these accomplishments and especially the partnership that we have been able to form with our Industry Board Members and other entities like the FDA.  We are looking forward to an even brighter third year.”

We are pleased to announce that this spring Dr. Anton Dmitriev officially became a US Food and Drug Administration (FDA) Liaison to the CDMI. In such capacity, Dr. Dmitriev will present and receive information and views on behalf of the FDA. This was made possible, in part, by the FDA’s involvement in the UCSF-Stanford Center of Excellence in Regulatory Science and Innovation (CERSI) – a collaboration amongst scientists at UC San Francisco, Stanford University, and the FDA to support collaborative projects in regulatory science.